Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer (a type of cancer that starts in the liver). HCC begins in the main type of liver cell, a hepatocyte. It is most common in people with chronic liver diseases such as cirrhosis caused by hepatitis B or hepatitis C.
Hepatocellular carcinoma (HCC) is treated at Dana-Farber/Brigham and Women's Cancer Center's (DF/BWCC) Liver Cancer Center.
Anything that increases your risk of getting a disease is called a risk factor. Having a risk factor does not mean that you will get cancer; not having risk factors doesn't mean that you will not get cancer. People who think they may be at risk should discuss this with their doctor.
Risk factors for hepatocellular carcinoma include:
Many patients do not have symptoms in the beginning stages of liver cancer. However, when they do appear, the following signs and symptoms may be present. Check with your doctor if you have any of the following:
The Liver Cancer Center at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) has deep expertise in treating hepatocellular carcinoma. The Center conducts crucial research and clinical trials to learn more about the disease and develop promising new treatments.
To determine the best treatment plan, our multidisciplinary team will consider the size and location of the hepatocellular carcinoma, the liver’s health and the patient’s overall health. Treatments may include:
Learn more about the Liver Cancer Center, our approach to patient treatment and care, and our innovative research on hepatocellular carcinoma.
New Patient Appointments